Free SO ORDERED - District Court of Delaware - Delaware

Case 1 :08-cv-00162-JJF Document 20 Filed 06/20/2008 Page 1 of 3
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
1
Pfizer Inc., )
Pfizer Ireland Pharmaceuticals, )
Warner-Lambert Company, )
Warner-Lambert Company LLC and )
Warner-Lambert Export Limited, )
)
Plaintiffs/Counterclaim-Defendants )
)
v. )
) C.A. No. 08-cv-l62—J.IF
1
Ranbaxy Laboratories Limited )
Ranbaxy Pharmaceuticals, Inc. and )
Ranbaxy, Inc, )
1
Defendant/Counterclaim-Plaintiff )
CONSENT ORDER AND STIPULATED INJUNCTION
WHEREAS, plaintiffs/counterclaim defendants Pfizer Inc., Pfizer Ireland
Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company, LLC and
Warner-Lambert Export Limited ("Pfizer") own U.S. patents covering the manufacture,
sale and use of products containing atowastatin and amlodipine, and any
pharmaceutically acceptable salts thereof, including without limitation U.S. patents
6,087,511 and 6,274,740 (collectively, "Process Patents");
WHEREAS, defendant/counterclaim plaintiff Ranbaxy Laboratories Limited and
Ranbaxy, Inc. ("Ranbaxy") has submitted to the U.S. Food and Drug Administration
Abbreviated New Drug Application No. 78-747 ("Ranbaxy ANDA") for approval to

Case 1:08-cv-00162-JJF Document 20 Filed 06/20/2008 Page 2 of 3
market and sell a generic product containing atorvastatin calcium and amlodipine
besylate;
WHEREAS, Pfizer and Ranbaxy are parties to litigation relating to the Ranbaxy
ANDA and Process Patents, and Ranbaxy desirest 0 sell a generic product containing
atorvastatin calcium and amlodipine besylate under the Ranbaxy ANDA iiee from claims
of iniiingement by Pfizer under the Process Patents;
WHEREAS, Pfizer andR anbaxy have entered intoa Settlement andL icense
Agreement, dated as of June 17, 2008 ("Settlement Agreement"), pursuant to which the
parties have resolved this action and Pfizer has granted Ranbaxy certain rights to its
portfolio of patents relating to atorvastatin;
NOW THEREFORE, Pfizer and Ranbaxy stipulate that:
1. Ranbaxy, its officers, agents,s ervants, employees and attorneys, and those
persons in active concert or participation with Ranbaxy are enjoined until November 30,
201 1 fiom engaging in the commercial manufacture, use, offer to sell, or sale within the
UnitedS tates, or importationi ntot he UnitedS tates, of any product comprising the
chemical compounds atorvastatin calcium and amlodipine besylate. This injunction shall
terminate automatically upon the U.S. Generic Lipitor Commencement Date as defined in
the Settlement Agreement.
2. The Protective Order entered by the Court in this action shall remain in
full force and effect notwithstanding this Consent Order and Stipulated injunction.
3. All claims and counterclaims are dismissed with prejudice, and each Party
shall bear its own costs, expenses and attorneys’ fees in connection with this action.
4. The parties waive any right of appeal from this Order.
2

Case 1:08-cv-00162-JJF Document 20 Filed 06/20/2008 Page 3 of 3
5. The Court reserves jurisdiction over this Consent Order in the evento f any
dispute concerning it.
Dated: June 18,200 8 Dated: June 18, 2008
By: /s/ Rudolf E. Hutz By: /s/ Frederick L. Cottre//, III
Rudolf E· Hutz (#484) Frederick nc ottrell, 111 (#2555)
Jeffrey B- BeVe (#998) Email: [email protected]
MMV W- Bourke (#2356) Richards, Layton & Finger
CONNOLLY BOVE LODGE & HUTZ LLP 0no Rodney Sqnoio
The Nemours Building p_(_)_ Box 55]
1007 North Orange Street Wilmington, DE igggg
PQ- BOX 2207 (302) 658-6541
Wllmmgtem DE 198992207 Attorneys jbr Defendants
(302) 658-9l4l
Attorneys for the P/aint#* (jfcounsoii
Joseph M. Reisman
William R. Zimmerman
Payson LeMeilleur
KNOBBE, MARTENS, OLSON
& BEAR, LLP
2040 Main Street, 14th Floor
Irvine, CA 92614
(949) 760-0404
Attorneys for Defendants
IT IS SO ORDERED, this 8`QD day of , 2008.
` » , `
AlLc..r.4& W
Honor ble eph J. Farnan,
ted States District Judge
3

Case 1:08-cv-00162-JJF

Document 20

Filed 06/20/2008

Page 1 of 3

Case 1:08-cv-00162-JJF

Document 20

Filed 06/20/2008

Page 2 of 3

Case 1:08-cv-00162-JJF

Document 20

Filed 06/20/2008

Page 3 of 3